AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

Key Inclusion Criteria:

• Participant with clinical diagnosis of acne vulgaris, defined by:

1. moderate acne on the face (acne Investigator's Global Assessment [IGA] =3); and
2. with minimum of 20 inflammatory lesions and 25 non inflammatory lesions on theface (excluding the nose); and
3. moderate to marked PIH on the face (Overview of Pigmentation Disordershyperpigmentation scale 4-6); and
4. no more than one acne nodule or cyst (greater than [>] 1 centimeter [cm]) on face (excluding the nose)

• Participant with any Fitzpatrick Skin Type I to VI (target patient enrollmentaccording to FST)
• Female participants of childbearing potential must have a negative urine pregnancytest (UPT) at Baseline visit
• Female participants of childbearing potential must agree to use an adequate andapproved method of contraception throughout the study
• Female participant of non-childbearing potential
• Other protocol defined inclusion criteria could apply

Key Exclusion Criteria:

• Participant with severe acne (IGA > 3)
• Participant with more than 1 nodule/cyst on the face (excluding the nose)
• Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne,acne requiring systemic treatment
• Participant with damaged facial skin that may interfere with study assessments
• Female participant who is pregnant, lactating or planning a pregnancy during the study
• Female participant of childbearing potential using combined oral contraceptivesapproved as acne treatments, in whom the dose has not been stable for at least 6months prior to the Baseline visit
• Participant with known impaired hepatic or renal functions
• Participant with active or chronic skin allergies